VectorY Therapeutics Appoints Olga Uspenskaya-Cadoz as Chief Medical Officer
VectorY Therapeutics, a biotechnology company advancing vectorized antibody therapies for neurodegenerative diseases, today announced the appointment of Olga Uspenskaya-Cadoz, M.D., Ph.D., as Chief Medical Officer (CMO).
VectorY Strengthens Leadership Team with Appointment of Jim Scibetta as New CEO
VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer.
VectorY Appoints Seasoned Biotech Leader Adam Rosenberg as Chair of the Board
VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Adam Rosenberg as the new Chair of the Board.
VectorY Appoints Khurem Farooq to Board of Directors
VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced the appointment of industry veteran Khurem Farooq as independent board member, effective immediately.
VectorY Announces Participation in Scientific Conferences in October 2022
VectorY Therapeutics, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of neuro-degenerative and muscular disorders through vectorized antibodies, today announces participation in three upcoming conferences.
VectorY to Present Two Posters at the American Society of Gene and Cell Therapy’s (ASGCT) 25th Annual Meeting
VectorY Therapeutics, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of muscular and neurodegenerative disorders through vectorized antibodies, today announces the presentation of two posters at the American Society of Gene and Cell Therapy’s (ASGCT) 25th Annual Meeting at the Walter E. Washington Convention Center in Washington, D.C. on May 16-19, 2022. Members of the VectorY team will attend the conference in person and be available to discuss the posters.
